TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Scanning Babies for Autism A study found that babies and children with autism reacted to hearing bedtime stories in different areas of their brains when compared with their typically-developing peers. online.wsj.com |
Pfizer Halts Trial of Pain Drug: Biotech's Latest Mishaps The Burrill Report submits: Pfizer (PFE) said it was halting a trial of its experimental drug tanezumab to treat chronic low back pain and diabetic peripheral neuropathy at the request of the U.S. Food and Drug Administration. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain, the pharmaceutical company said. The FDA's request follows reports of adverse events in osteoarthritis patients taking tanezumab, and the agency's concerns regarding the potential for such events in other patient populations in which the compound is being studied. Pfizer said it will continue to work with the FDA to reach a common understanding about the appropriate scope of continued clinical investigation of tanezumab. A U.S. Food and Drug Administration panel is advising the agency to revoke Roche's (RHHBY.PK) right to market Avastin as a treatment for metastatic breast cancer after additional trial data convinced it that the biologic's risks might outweigh its benefits. The recommendation could put a $1 billion dent in Avastin's global sales some reports say, slicing as much as a sixth off Roche's $6 billion take from the drug in 2009 and opening up fears that European regulators may also revisit their approval of the drug's use in treating advanced breast cancer. Complete Story » seekingalpha.com |
Quest Diagnostics Declares Quarterly Cash Dividend (PR Newswire) Quest Diagnostics Incorporated , the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on October 19, 2010, to shareholders of record of Quest Diagnostics common stock on October 4, 2010. us.rd.yahoo.com |
MEDTOX Scientific Announces Third Quarter Conference Call [GlobeNewswire] - ST. PAUL, Minn. -- MEDTOX Scientific, Inc. , announced today that it will hold a teleconference to discuss third quarter results on Wednesday, October 13, at 9:30 a.m. Central Time . us.rd.yahoo.com |
Zalicus: Ridiculously Cheap Jeremy Richards submits:CombinatoRx (formerly CRXX) recently changed its name to Zalicus (ZLCS) - a healthy positioned biopharmaceutical company with new and existing product developments. Zalicus is considerably undervalued. and should easily be trading double its current stock price. Zalicus discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The company's clinical and preclinical product candidates for pain, inflammation, and other central nervous system disorders include Synavive (CRx-102), a novel dissociated glucocorticoid product candidate, which has completed Phase II clinical trials in subjects with knee osteoarthritis, to treat immuno-inflammatory disorders; Prednisporin (FOV1101), a topical ophthalmic drug candidate containing low doses of the glucocorticoid prednisolone acetate and the immunosuppressant cyclosporine A; N-type and T-type calcium channel blockers for the treatment of chronic pain; and CRx-601, a formulation of carbidopa and levodopa for the treatment of Parkinsons disease. It is also developing CRx-401 for Type 2 diabetes; CRx-191 and CRx-197 for psoriasis. It has a research collaboration and license agreement with the Novartis (NVS) Institutes of Biomedical Research; a collaboration agreement with PGxHealth, LLC for the development of ATL313, an adenosine A2A receptor agonist compound owned by PGxHealth; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and National Institutes of Allergy and Infectious Diseases; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases.Complete Story » seekingalpha.com |